Kidney transplant hope: drug may remove antibody barriers

NCT ID NCT04294459

Terminated Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early study tested a drug called isatuximab in 23 people waiting for a kidney transplant. The goal was to see if it could safely lower immune antibodies that make it hard to find a matching donor. The trial was stopped early, so we have limited information on how well it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: isatuximab (Sarclisa)
What this could lead to: If it worked, this could help more people with kidney failure find a compatible donor and receive a transplant.
What could go wrong: This was a very early (phase 1/2) trial that was terminated, so we don't know if it works. The drug can cause infusion reactions and other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease immune system disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IMMUNE SYSTEM DISORDER

Contacts and locations

Locations

Investigational Site Number :7240001

L'Hospitalet de Llobregat, Catalunya [Cataluña], 08907, Spain
Investigational Site Number :7240002

Barcelona, Barcelona [Barcelona], 08035, Spain
Investigational Site Number :8400001

Rochester, Minnesota, 55905, United States
Investigational Site Number :8400002

New York, New York, 10016, United States
Investigational Site Number :8400003

San Francisco, California, 94143, United States
Investigational Site Number :8400004

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.